FierceBiotech

PRESS RELEASE: Aclasta receives European approval as first once-yearly treatment for postmenopausal osteoporosis

Shown to be highly effective in strengthening bones and protecting against fractures in all key sites, including hip and spine[1] Once-yearly dosing provides potential for compliance benefits and long ...
FiercePharma

Long-term data show Novartis once-yearly Aclasta preserves bone mass and provides fracture protection in postmenopausal osteopor

Aclasta reduced the risk of new spine fractures by 52% over six years versus patients who stopped treatment after three years[1] New data from six-year study validate Aclasta safety profile and ...
PharmaTimes

Novartis’ osteoporosis jab Aclasta shines in long-term trial

New long-term data for Novartis’ once-yearly osteoporosis jab Aclasta/Reclast have cemented its safety and efficacy profile, showing that the drug preserves bone mass and slashes the risk of new spine ...
PharmaTimes

Osteoporosis patients gain access to Novartis’ Aclasta

Patients in the UK will this week get access to Novartis’ annual postmenopausal osteoporosis drug Aclasta, following its European approval last Friday. Patients in the UK will this week get access to ...
Zawya

Aclasta® Approved in Jordan as the first once-yearly treatment for women with postmenopausal osteoporosis

01 February 2009Single-dose therapy given once a year shown to provide significant bone protection benefits and may improve long-term treatment compliance Amman - Jordan - Aclasta (zoledronic acid 5 ...
FierceBiotech

FDA says Aclasta "approvable" for Paget's

Switzerland's Novartis says it received an FDA "approvable" letter for Aclasta to treat Paget's disease of the bone. The FDA has requested additional data from an ongoing trial of the drug for ...
MarketWatch

Novartis says Aclasta approved for osteoporosis

LONDON (MarketWatch) -- Swiss drugmaker Novartis said Friday that its Aclasta medicine has been approved in the European Union to treat men and postmenopausal women with osteoporosis caused by ...
MarketWatch

Novartis gets E.U. nod for bone drug Aclasta

ZURICH (MarketWatch) -- Drugmaker Novartis AG NVS said Friday that the European Union regulator had approved its bone drug Aclasta, a treatment which needs to be taken only once a year.
Business Wire

Although Bisphosphonates Will Continue to Dominate Osteoporosis Treatment Through 2020, Patent Expiries of Risedronate, Reclast/Aclasta and Boniva/Bonviva Will Trigger a ...

BURLINGTON, Mass.--(BUSINESS WIRE)--Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that although bisphosphonates will ...
Medscape

International Approvals: Plan B, Sativex, Aclasta

April 25, 2005 — Health Canada has approved levonorgestrel emergency contraceptive for sale without a prescription to women aged 16 years and older, and an oral spray derived from components of the ...
FiercePharma

Novartis gains Aclasta, loses Prexige

From the good news, bad news file: Novartis got the EU's approval to sell its new osteoporosis drug Aclasta, known in the U.S. as Reclast. Reclast got the FDA's nod six weeks ago, and analysts are ...